Altimmune Analyst Ratings
Altimmune Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 401.67% | HC Wainwright & Co. | $50 → $15 | Maintains | Buy |
| 08/11/2023 | 401.67% | B. Riley Securities | $20 → $15 | Maintains | Buy |
| 07/12/2023 | 401.67% | JMP Securities | → $15 | Reiterates | Market Outperform → Market Outperform |
| 05/15/2023 | 1572.24% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 05/11/2023 | 401.67% | JMP Securities | $15 → $15 | Reinstates | Market Outperform → Market Outperform |
| 03/31/2023 | 401.67% | JMP Securities | → $15 | Reiterates | → Market Outperform |
| 03/22/2023 | 769.57% | JMP Securities | → $26 | Reiterates | → Market Outperform |
| 03/22/2023 | 100.67% | Goldman Sachs | $20 → $6 | Downgrades | Buy → Neutral |
| 03/09/2023 | 1572.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/06/2023 | 769.57% | JMP Securities | → $26 | Reiterates | → Market Outperform |
| 01/20/2023 | 1572.24% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 01/18/2023 | 736.12% | Evercore ISI Group | $14 → $25 | Maintains | Outperform |
| 12/01/2022 | 568.9% | Goldman Sachs | → $20 | Initiates Coverage On | → Buy |
| 11/11/2022 | 769.57% | JMP Securities | $28 → $26 | Maintains | Market Outperform |
| 09/16/2022 | 769.57% | Guggenheim | $31 → $26 | Maintains | Buy |
| 08/31/2022 | 1070.57% | Jefferies | $30 → $35 | Maintains | Buy |
| 08/17/2022 | 1572.24% | HC Wainwright & Co. | $25 → $50 | Maintains | Buy |
| 08/12/2022 | 769.57% | B. Riley Securities | $21 → $26 | Maintains | Buy |
| 05/18/2022 | 736.12% | Piper Sandler | $34 → $25 | Maintains | Overweight |
| 06/30/2021 | 602.34% | B. Riley Securities | $41 → $21 | Maintains | Buy |
| 06/30/2021 | 936.79% | JMP Securities | $53 → $31 | Maintains | Market Outperform |
| 06/30/2021 | 736.12% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 06/16/2021 | 1672.58% | JMP Securities | $45 → $53 | Maintains | Market Outperform |
| 06/02/2021 | 1070.57% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 02/11/2021 | 1104.01% | Guggenheim | → $36 | Initiates Coverage On | → Buy |
| 11/24/2020 | 736.12% | Evercore ISI Group | → $25 | Reinstates | → Outperform |
| 09/25/2020 | 936.79% | B. Riley Securities | → $31 | Initiates Coverage On | → Buy |
| 07/31/2020 | 2575.59% | Piper Sandler | → $80 | Initiates Coverage On | → Overweight |
| 07/28/2020 | 1572.24% | JMP Securities | → $50 | Initiates Coverage On | → Market Outperform |
| 07/19/2019 | 177.59% | Roth Capital | → $8.3 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 401.67% | HC Wainwright公司 | $50→$15 | 維護 | 買 |
| 2023年08月11日 | 401.67% | B.萊利證券 | $20→$15 | 維護 | 買 |
| 07/12/2023 | 401.67% | JMP證券 | →$15 | 重申 | 市場表現優於→市場表現 |
| 2023年05月15日 | 1572.24% | HC Wainwright公司 | →$50 | 重申 | 購買→購買 |
| 2023年05月11日 | 401.67% | JMP證券 | $15→$15 | 恢復 | 市場表現優於→市場表現 |
| 03/31/2023 | 401.67% | JMP證券 | →$15 | 重申 | →市場跑贏大盤 |
| 03/22/2023 | 769.57% | JMP證券 | →$26 | 重申 | →市場跑贏大盤 |
| 03/22/2023 | 100.67% | 高盛 | $20→$6 | 評級下調 | 購買→中性 |
| 03/09/2023 | 1572.24% | HC Wainwright公司 | →$50 | 重申 | →購買 |
| 02/06/2023 | 769.57% | JMP證券 | →$26 | 重申 | →市場跑贏大盤 |
| 01/20/2023 | 1572.24% | HC Wainwright公司 | →$50 | 重申 | →購買 |
| 01/18/2023 | 736.12% | Evercore ISI集團 | $14→$25 | 維護 | 跑贏大盤 |
| 12/01/2022 | 568.9% | 高盛 | →$20 | 開始承保 | →購買 |
| 2022年11月11日 | 769.57% | JMP證券 | $28→$26 | 維護 | 市場表現強於大盤 |
| 09/16/2022 | 769.57% | 古根海姆 | $31→$26 | 維護 | 買 |
| 2022年08月31日 | 1070.57% | 傑富瑞 | $30→$35 | 維護 | 買 |
| 2022/08/17 | 1572.24% | HC Wainwright公司 | $25→$50 | 維護 | 買 |
| 2022年08月12日 | 769.57% | B.萊利證券 | $21→$26 | 維護 | 買 |
| 2022/05/18 | 736.12% | 派珀·桑德勒 | $34→$25 | 維護 | 超重 |
| 2021/06/30 | 602.34% | B.萊利證券 | $41→$21 | 維護 | 買 |
| 2021/06/30 | 936.79% | JMP證券 | $53→$31 | 維護 | 市場表現強於大盤 |
| 2021/06/30 | 736.12% | HC Wainwright公司 | $35→$25 | 維護 | 買 |
| 06/16/2021 | 1672.58% | JMP證券 | $45→$53 | 維護 | 市場表現強於大盤 |
| 06/02/2021 | 1070.57% | HC Wainwright公司 | →$35 | 開始承保 | →購買 |
| 02/11/2021 | 1104.01% | 古根海姆 | →$36 | 開始承保 | →購買 |
| 11/24/2020 | 736.12% | Evercore ISI集團 | →$25 | 恢復 | →跑贏大盤 |
| 09/25/2020 | 936.79% | B.萊利證券 | →$31 | 開始承保 | →購買 |
| 07/31/2020 | 2575.59% | 派珀·桑德勒 | →$80 | 開始承保 | →超重 |
| 07/28/2020 | 1572.24% | JMP證券 | →$50 | 開始承保 | →市場跑贏大盤 |
| 2019年07月19日 | 177.59% | 羅斯資本 | →$8.3 | 開始承保 | →購買 |
What is the target price for Altimmune (ALT)?
Altimmune(ALT)的目標價是多少？
The latest price target for Altimmune (NASDAQ: ALT) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $15.00 expecting ALT to rise to within 12 months (a possible 401.67% upside). 17 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年8月14日報道了Altimmune(納斯達克：ALT)的最新目標價。這家分析公司將目標價定為15美元，預計ALT將在12個月內上漲至(可能上漲401.67%)。過去一年，17家分析公司公佈了評級。
What is the most recent analyst rating for Altimmune (ALT)?
Altimmune(ALT)的最新分析師評級是多少？
The latest analyst rating for Altimmune (NASDAQ: ALT) was provided by HC Wainwright & Co., and Altimmune maintained their buy rating.
分析師對Altimmune(納斯達克代碼：ALT)的最新評級由HC Wainwright&Co.提供，Altimmune維持買入評級。
When is the next analyst rating going to be posted or updated for Altimmune (ALT)?
Altimmune(ALT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Altimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Altimmune was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Altimmune的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Altimmune的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右的某個時候公佈。
Is the Analyst Rating Altimmune (ALT) correct?
分析師對Altimmune(ALT)的評級正確嗎？
While ratings are subjective and will change, the latest Altimmune (ALT) rating was a maintained with a price target of $50.00 to $15.00. The current price Altimmune (ALT) is trading at is $2.99, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Altimmune(ALT)評級維持不變，目標價在50.00美元至15.00美元之間。Altimmune(ALT)目前的交易價格為2.99美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。